Tier 4 — mechanistic

Preclinical and clinical evidence of NAD + precursors in health, disease, and ageing

Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF
Mechanisms of ageing and development 2021 199; 111567

Bibliography

PubMed
PMID 34517020
DOI
10.1016/j.mad.2021.111567
Funding
Funding details are not specified in the accessible publication information.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignNarrative evidence review
ModelPublished preclinical and clinical literature
SamplePreclinical and human NAD+-precursor literature
InterventionNR, NMN, NRH and related precursor strategies
DurationPublished 2021 review
EndpointsEvidence synthesis and translational limitations

What the study showed, in plain terms

The review surveyed biological activity, safety and therapeutic hypotheses across several NAD+ precursors.

Key findings

The review surveyed biological activity, safety and therapeutic hypotheses across several NAD+ precursors.

What this study can and cannot tell us

Different precursor chemistry, models and endpoints limit direct comparisons; the review predates many current human NR trials.

Related papers in the corpus

Tier 4
Emerging strategies, applications and challenges of targeting NAD + in the clinic
Zhang J et al. · Nature aging · 2025
Tier 4
What is really known about the effects of nicotinamide riboside supplementation in humans
Damgaard MV et al. · Science advances · 2023
Tier 4
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions
Freeberg KA et al. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2023
Tier 4
NAD + Precursors in Human Health and Disease: Current Status and Future Prospects
Yaku K et al. · Antioxidants & redox signaling · 2023
Tier 4
Balancing NAD + deficits with nicotinamide riboside: therapeutic possibilities and limitations
Cercillieux A et al. · Cellular and molecular life sciences : CMLS · 2022
Tier 1
Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis
Zhong O et al. · Nutrition & metabolism · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology